Andrew Huberman· PhD
in clinical studies they're exploring set and setting — as maybe the factors that have in the past historically given very unpredictable outcomes for psychedelic therapies — it's possible that it's set and setting it's also possible that there's individual variability it's possible that there are biomarkers that can predict which individuals would be well suited for this type of therapy